HC Wainwright Has Negative Outlook of AKRO FY2024 Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Investment analysts at HC Wainwright dropped their FY2024 EPS estimates for Akero Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst E. Arce now expects that the company will earn ($3.90) per share for the year, down from their prior estimate of ($3.44). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.94) per share. HC Wainwright also issued estimates for Akero Therapeutics’ Q4 2024 earnings at ($1.13) EPS, Q1 2025 earnings at ($1.16) EPS, Q2 2025 earnings at ($1.19) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.77) EPS, FY2026 earnings at ($3.91) EPS and FY2027 earnings at ($1.17) EPS.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15).

Akero Therapeutics Price Performance

Akero Therapeutics stock opened at $28.09 on Thursday. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -7.43 and a beta of -0.26. The firm’s fifty day moving average is $29.43 and its 200 day moving average is $25.53. The company has a quick ratio of 24.89, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics has a 52-week low of $13.86 and a 52-week high of $37.00.

Insider Activity at Akero Therapeutics

In other news, insider Catriona Yale sold 15,485 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $32.62, for a total value of $505,120.70. Following the transaction, the insider now directly owns 74,158 shares in the company, valued at approximately $2,419,033.96. This represents a 17.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO William Richard White sold 75,159 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $27.21, for a total transaction of $2,045,076.39. Following the completion of the transaction, the chief financial officer now owns 41,791 shares in the company, valued at approximately $1,137,133.11. The trade was a 64.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 428,397 shares of company stock valued at $12,997,971 over the last 90 days. 7.94% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AKRO. Swiss National Bank grew its holdings in shares of Akero Therapeutics by 19.9% in the first quarter. Swiss National Bank now owns 105,000 shares of the company’s stock worth $2,652,000 after purchasing an additional 17,400 shares during the last quarter. Headlands Technologies LLC grew its holdings in Akero Therapeutics by 253.5% during the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock worth $107,000 after acquiring an additional 3,024 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Akero Therapeutics by 2,366.0% during the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after acquiring an additional 1,183 shares in the last quarter. ProShare Advisors LLC grew its holdings in Akero Therapeutics by 24.4% during the 1st quarter. ProShare Advisors LLC now owns 15,001 shares of the company’s stock worth $379,000 after acquiring an additional 2,945 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Akero Therapeutics by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after buying an additional 584,875 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.